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life. When possible, meta-analysis was performed, evaluating the presence of het-
erogeneity and risk of publication bias. Otherwise, descriptive analysis of the avail-
able data was done. Results: Of the 10.348 original references scanned, 17 studies 
were finally selected, 7 experimental and 10 analytical. The population included 
was mainly adults, with type 2 diabetes. Important risk of bias was found in all of 
the articles, particularly the experimental ones. Meta-analysis was performed for 
glycemic control, hypoglycemia, adherence and persistence. Pen devices showed 
better results in mean HbA1c change, frequency of hypoglycemia, adherence and 
persistence compared to vial and syringes. No difference was observed in number 
of patients achieving < 7% of HbA1c. Studies regarding preference showed a clear 
tendency favorable to pen devices, but measurement methods were generally not 
well validated. One study on quality of life showed improvements in some subscales 
of SF-36. ConClusions: There is evidence that pen devices offer benefits regarding 
glycemic control, hypoglycemia, adherence, persistence, patient preference and 
quality of life compared to vial and syringes for insulin administration. However, 
data had considerable risk of bias, more methodologically sound studies are needed.
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objeCtives: Several GLP-1 receptor agonists are available as weekly injections for 
treatment of type 2 diabetes. These medications vary in their injection delivery 
systems, and these differences could impact quality of life and patient preference. 
The purpose of this study was to estimate utilities associated with injection deliv-
ery systems for weekly GLP-1 therapies. Methods: Participants diagnosed with 
type 2 diabetes in the UK (Inverness, Portree, Edinburgh, London) valued health 
states in time trade-off (TTO) interviews. The health states (drafted based on lit-
erature, device instructions for use, and clinician interviews) had identical descrip-
tions of type 2 diabetes, but differed in description of the treatment process. One 
health state described an oral only treatment regimen (i.e., tablets), while six 
health states described oral treatment plus a weekly injection. The injection health 
states differed in the treatment administration process (e.g., requirements for 
reconstituting the medication, waiting during medication preparation, and nee-
dle handling). Results: A total of 209 participants completed interviews (57.4% 
male; mean age = 60.4y; 150 patients from Scotland and 59 from London). The 
mean (SD) utility of the oral treatment health state was 0.89 (0.12), and all injec-
tion health states had significantly (all p < 0.01) lower utilities ranging from 0.86 
(reconstitution, waiting, and handling) to 0.88 (weekly injection without any of the 
three treatment administration requirements). Utility differences among the injec-
tion health states suggest that each administration requirement had a small but 
measureable disutility (i.e., negative utility difference). Disutility values include 
-0.004 (reconstitution), -0.004 (needle handling), -0.010 (reconstitution, needle 
handling), and -0.020 (reconstitution, waiting, needle handling). ConClusions: 
Findings suggest that the TTO method may be used to quantify preferences among 
different injection treatment processes. It may be useful to incorporate these dif-
ferences into cost-utility models comparing among weekly injectable treatment 
for patients with type 2 diabetes.
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objeCtives: Glucose monitoring is particularly important for patients with diabetes 
treated with insulin. Conventional self-monitoring of blood glucose (SMBG) requires 
a blood sample, typically obtained by pricking the finger with a lancing device. A 
new device (FreeStyle Libre™ flash glucose monitoring system) has been developed 
to monitor glucose levels with a sensor worn on the arm, without requiring blood 
samples. This study estimated utility associated with these two glucose monitoring 
approaches so that the values may be used in cost-utility models. Methods: In 
time trade-off (TTO) interviews, general population participants in the UK (London, 
Edinburgh) valued two health states which were drafted based on literature and 
clinician interviews. The health states had identical descriptions of diabetes and 
insulin treatment, but differed in glucose monitoring with either the FreeStyle 
Lite™ (SMBG) or the FreeStyle Libre (flash monitoring) system. Results: A total 
of 209 participants completed interviews (51.7% female; mean age = 42.1 y). Mean 
(SD) utilities were 0.851 (0.140) for SMBG and 0.882 (0.121) for flash monitoring 
(significant difference between the mean utilities; t = 8.3; p < 0.0001). Of the 209 
participants, 78 (37.3%) had a higher utility for flash monitoring, two (0.96%) had a 
higher utility for SMBG, and 129 (61.7%) had the same utility for both health states. 
The mean score on a seven-point preference scale ranging from strongly prefer flash 
monitoring (1) to strongly prefer SMBG (7) indicates that the participants generally 
preferred the flash monitoring system (mean = 1.8; SD = 1.5). ConClusions: The 
flash monitoring system was associated with significantly greater utility than SMBG. 
This difference can be used in cost-utility models, comparing the value of glucose 
monitoring devices for patients with diabetes. This study also demonstrates that the 
TTO method may be used to quantify preferences for medical devices.
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objeCtives: Analysis of acceptability and effectiveness of upper limb rehabilitation 
treatments based on two robotic systems in stroke patients. Methods: Two specific 
Budesonide combination. For retired patients, visiting the GP increased the probabil-
ity of medication compliance. ConClusions: We concluded that inhaler devices 
influence patients’ compliance for long-term asthma medication. The impact of 
DPI on medication compliance was negative. We also identified some confounders 
of medication compliance such as patient’s age, severity of asthma, comorbidities 
and healthcare costs.
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objeCtives: This single-site, cross-over study evaluated device mastery with dry 
powder inhalers, Spiromax®, Easyhaler® and Turbuhaler®. Methods: Healthy 
inhaler-naïve participants aged ≥ 18 years (N= 120) were observed using each of 
the three empty devices (Spiromax, Easyhaler, and Turbuhaler) in a counter-bal-
anced order. To evaluate the proportion of participants achieving device mastery 
(defined as an absence of health care professional [HCP] observed errors), a three 
step approach was used: 1) intuitive use (no instructions), 2) use after reading the 
patient information leaflet (PIL) user instructions and 3) use after HCP instructions. 
Trained HCPs monitored use and recorded errors based on device-specific handling 
error checklists. Results: During steps 1 and 2, respectively, more participants 
used Spiromax without error (37.5% and 93.3%; p< 0.001) compared with Easyhaler 
(0% and 58.3%) and Turbuhaler (9.2% and 76.7%); performance level was high (> 95%) 
with all devices during step 3. The mean proportion of errors committed by partici-
pants in steps 1 and 2 was lower with Spiromax (12.4%, 0.8%; p< 0.001) compared 
with Easyhaler (18.7%, 5.0%) and Turbuhaler (17.6%, 2.8%); the proportion of errors 
for each device was similar in step 3 (0.1%, 0.5%, 0.1%, respectively). The most com-
mon errors in step 1 were related to orientation for Spiromax (51.3%), shaking for 
Easyhaler (95.8%), and priming for Turbuhaler (55.8%). All findings were independent 
of age, gender, and education level. ConClusions: Spiromax was associated with 
higher levels of device mastery evidenced by intuitive use (no instructions) or PIL 
information, and fewer errors compared with Easyhaler and Turbuhaler. The most 
common errors associated with Spiromax were related to orientation. Assessing 
device mastery and providing training can improve drug effectiveness which may 
affect adherence and overall treatment costs.
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objeCtives: Patient preference and overall satisfaction with their inhaler is cor-
related with improved adherence, better clinical outcomes and reduced costs. 
This single-site, cross-over study evaluated preference with dry powder inhal-
ers, Spiromax®, Easyhaler® and Turbuhaler®. Methods: Healthy inhaler-naïve 
participants aged ≥ 18 years (N= 120) were observed using each of the three empty 
devices (Spiromax, Easyhaler, and Turbuhaler) in a counter-balanced order. A three 
step approach was used: 1) intuitive use (no instructions), 2) use after reading the 
patient information leaflet (PIL) user instructions, and 3) use after health care 
professional instructions. Devices were rated using a device preference question-
naire after participants completed the three steps with each device. Participants 
were also asked to rate their satisfaction (on a scale from 1 [unsatisfactory] to 
5 [excellent]) with the following features: 1) overall ease of use, 2) quality of PIL 
instructions, 3) preparing the dose, 4) inhaling procedure, and 5) clarity of dose 
counter. Results: Spiromax was rated as the easiest device to use by 73.1% of 
participants, and 71.4% reported that if prescribed an inhaler they would prefer 
Spiromax. In comparison, 12.6% rated Easyhaler and 14.3% rated Turbuhaler as 
easiest to use; 16.8% and 11.8% would prefer Easyhaler and Turbuhaler, respec-
tively, if prescribed an inhaler. Participants rated Spiromax significantly higher 
compared to both Easyhaler and Turbuhaler (p< 0.001 for all comparisons) for all 
features except inhaling procedure, where no differences were found. Differences 
between Easyhaler and Turbuhaler were not significant with regards to any of the 
features analyzed except quality of PIL instructions, where Turbuhaler received 
higher ratings (p< 0.003), and clarity of the counter, where Easyhaler received 
higher ratings (p< 0.015). ConClusions: This study suggests that, if prescribed 
an inhaler product, device-naïve users prefer Spiromax and find it to be more 
intuitive in comparison to Easyhaler and Turbuhaler.
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objeCtives: Studies suggest that “pen” devices offer advantages over traditional 
vial and syringe method for insulin administration. Our purpose was to evalu-
ate their efficacy safety and patient preference through a systematic review and 
meta-analysis. Methods: A systematic review was performed using an expert-
approved PICO question, in 8 different databases. References were screened by 
two independent investigators. Primary observational or experimental full articles 
comparing pen devices with vial and syringes for insulin administration in adults 
with diabetes mellitus were included (except gestational diabetes). Manual search 
for additional references was performed on selected articles. Risk of bias was evalu-
ated using the appropriate tools. We collected data on glycosylated hemoglobin 
(HbA1c), hypoglycemia, adherence, persistence, patient preference and quality of 
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objeCtives: This study examines the impact of reference pricing on the price 
and spending for in vitro laboratory tests for a large private employer in the United 
States. Methods: We obtained comprehensive laboratory and medical claims for 
employees of a major US firm from 2009 to 2013. Each claim contained the CPT code for 
the test, the price paid (allowed charge), and the identity and the location of the labora-
tory. We matched lab claims to medical claims for the patients, obtaining information 
on age, gender, diagnoses and co-morbidities (ICD9). Beginning in January 2011, the 
firm limited its payment for 566 in vitro laboratory tests to the 60th percentile in the 
price distribution for each test across national laboratories, hospital-based laboratories, 
and freestanding local laboratories. Reference-priced tests generated 99,225 individual 
patient assays and insurance claims. Another 247 types of in vitro tests were exempted 
from reference pricing; these generated 33,480 individual patient assays and insurance 
claims. We used difference-in-difference multivariable regression analysis (GLM with log 
link and gamma distribution) to measure the rate of change in prices paid per test for 
laboratory tests subject to reference pricing, compared to the change in prices paid for 
laboratory tests exempted from reference pricing. Results: Reference pricing led to a 
17.8% (p< .001) reduction in laboratory test prices paid in the first year after implementa-
tion. By the second year, this had increased to 21.6% (p< .001) and by the third year to a 
27.7% (p< .001) reduction. In the three years after implementation of reference pricing, 
the employer saved 18.5% in spending compared to what it would have spent had the 
prices of reference-priced tests continued to increase at the same rate as non-reference 
priced tests. ConClusions: Reference pricing reduces prices paid per test and total 
spending on laboratory tests in the United States.
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objeCtives: Education and product training are critical but overlooked variables in 
the value assessment of medical devices. By example, over 24 million insulin injec-
tions occur daily in Europe, with little knowledge on proper injection technique (IT).1 
This case study illustrates the positive impact of insulin IT education on diabetes 
outcomes, drug consumption and healthcare costs. Methods: We conducted a 
literature review on diabetes IT. The impact of IT education on adherence, adverse 
events, insulin consumption, and glycemic control were appraised in the context 
of i) Proper device selection; ii) Education, application, and adherence to IT best 
practices; and; iii) adverse event monitoring. Potential healthcare savings from a 
UK NHS perspective were estimated using probabilistic patient simulations based 
on risk equations from the UKPDS study.2 Results: Evidence suggests the clinical 
benefits of IT best practices include 1) better patient acceptability via overall prefer-
ence and lower injection pain (VAS significantly less with shorter needle, sharper 
tips; p< 0.001)3 2), associations between not rotating injection sites (poor IT practice) 
and increased prevalence of lipohypertrophy, > 30% higher insulin consumption 
and worse glycaemic control4 (HbA1c 0.5% higher in patients with lipohypertrophy 
(p= 0.003)5, and 3), lower risk of intramuscular injections with proper device selec-
tion (0.4% – 1.8% for 4 and 5mm needles)6. Another prospective non-controlled 
study, investigating the impact of individualized IT education including site rotation 
and use of short needles, in patients taking insulin for more than 4 years, identified 
a mean HbA1c reduction of 0.58% and reduced insulin consumption by 2 units/day 
within 3 months (both, p< 0.05).7 Over 10 years, savings could range from £12-25 mil-
lion and potential insulin savings of £5 million per 100,000 people. ConClusions: 
The value assessment of medical devices should include HCP/patient education as 
clinical outcomes and cost savings are material. This is exemplified vis-à-vis proper 
education on diabetes IT for people on insulin.
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objeCtives: The diagnosis and treatment of Healthcare Associated Infections (HAI) 
have a significant impact on the care pathways and hospital costs; one of the most 
diffused HAI is Clostridium Difficile (CDI). The study aimed to assess the CDI distri-
bution, related costs and possible areas of saving. Methods: Patients admitted at 
the TorVergata University Hospital between January and December 2013 presenting a 
CDI diagnosis were identified by analysing the Microbiology Laboratory Information 
Flow. Turn-Around-Time(TAT) was used to assess the efficiency of diagnosis with 
cultural exam and PCR methodologies. Through the analysis of clinical records, the 
CDI distribution in hospital departments and DRGs were examined. The economic 
value associated to each admission was calculated. Results: In the considered 
period, 1769 CDI tests were performed. 752 were valid for the analysis, 170 tests (22%) 
were positive and corresponded to 94 admissions. The TAT analysis showed that the 
PCR allowed saving about three days, compared to the cultural exam. The incidence 
of CDI was 8.2cases per 10,000bed-days/patient. More than half of cases were in: 
General Medicine(27;29%); Gastroenterology(14;15%); casualty department(12;13%); 
Infectious Diseases, respiratory Medicine, onco-haematology(respectively9;10%). 
ALOS was 31.8days (between5-132). The five most frequent DRGs were: DRG-572.
Gastrointestinal and peritoneal infections(n= 10), DRG-576.Septicemia without 
questionnaires based on a 0-7 points Likert scale were delivered to n= 10 subacute 
stroke patients affected by upper limb hemiparesis and n= 23 physiotherapists using 
two different robotic systems (InMotion2, Interactive Motion Technologies, USA and 
Armeo Spring, Hocoma AG, Switzerland). The (i) perceived comfort and effectiveness 
of robot-assisted rehabilitation treatments and (ii) evaluation of human-robot inter-
action was investigated. An economic analysis of costs associated to the introduc-
tion of robotic technology into clinical practice was carried out as well. Results: 
Stroke patients consider the upper limb robot-assisted rehabilitation treatment as 
positive (mean score 5.80±0.89) and 96% of them consider it as safe. An higher score 
associated to the desire of continuing the robotic therapy (mean score 6.30±0.82) 
than that reported by physiotherapists (mean score 5.31±1.66) was found. Positive 
evaluations by patients on usefulness, satisfaction and desire to continue highlight 
the potential effectiveness of the robotic treatment. Results from physiotherapists 
confirm the positive attitude towards robotic technology (mean score 6.12±0.66), 
especially in terms of safety and satisfaction. Direct and indirect costs associated 
to upper limb robot-assisted rehabilitation treatment and traditional manual physi-
otherapy have been found to be comparable. ConClusions: The perceived effec-
tiveness and acceptability of robotic technology for upper limb rehabilitation were 
positively evaluated both by stroke patients and physiotherapists. The initial high 
economic investment in robotic technology should be considered as associated to 
the optimization of healthcare resources. Further analyses on the effects of the 
robot-assisted rehabilitation treatments on the quality of life of patients have to 
be carried out through large multicentric RCTs.
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objeCtives: This study aimed at assessing patient preferences for different 
characteristics of Dry Powder Inhalers (DPIs) from patients with asthma and 
chronic obstructive pulmonary (COPD) disease in France, UK, Spain, Germany 
and Netherlands using the discrete choice experiment (DCE) method. Methods: 
Attributes characterizing DPIs and attribute levels were defined using focus groups 
among asthma and COPD patients and interviews of health care professionals in 
France. Those attributes were ease of use, accurate and easy-to-read dose coun-
ter, dose confirmation, hygiene of the mouthpiece, flexibility of device handling 
and use with breathing difficulties. A fractional factorial design including 3 sets 
of 12 choices was created. Analyses were performed using a ranked ordered logit 
model. Interactions between attributes and asthma/COPD were tested. Results: 
Participants included 601 patients with asthma and 491 with COPD. Asthma and 
COPD patients were on average 43 and 53 years old respectively. Preferences of 
patients with asthma and COPD were largely similar, but the marginal utility of the 
cost attribute was higher in asthma patients, compared to COPD, in three countries. 
In all countries, marginal utilities were highest for ease of use and ability to use 
the inhaler with breathing difficulties. Estimates of willingness to pay (WTP) for an 
inhaler requiring one step to prepare a dose instead of four ranged from € 3.27 (95% 
CI: [2.23;4.32]) in asthma patients in Germany to € 15.14 [-82.43;112.72] in asthma/
Spain. The estimated WTP for ability to use with breathing difficulties ranged from 
€ 2.19 [1.10;3.28] in asthma patients in the Netherlands and € 13.68 [-117.77;145.12] 
in COPD/Spain. The marginal utility of the hygiene of the mouthpiece was not sig-
nificantly different from zero. ConClusions: Despite differences in valuations 
of attributes between counties, two attributes were consistently found to be the 
most important: ease of use and ability to use the inhaler in case of difficulties 
breathing in.
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objeCtives: With the number of different hearing implants available for indi-
viduals with a conductive/mixed hearing loss (CMHL), it is becoming more and 
more important to demonstrate user needs and benefit, in particular for aiding in 
decision making. The aim of this study was to systematically review the subjective 
outcomes of different hearing implants for individuals with CMHL. Methods: 
Several databases were searched using a comprehensive search strategy to iden-
tify studies published assessing subjective outcomes with unilateral middle ear 
implantations (MEI), percutaneous bone conduction implants (pBCI) and transcu-
taneous BCIs (tBCI). The search included papers in any language. Non-systematic 
reviews, case reports, letters, editorials; animal, in-vitro and laboratory studies 
and clinical studies with less than 5 cases were excluded. Results: Out of 670 
citations, 22 percutaneous and 7 transcutaneous BCI, plus 10 MEI publications were 
identified (total n= 1106). As many as 20 different questionnaires were applied. All 
devices lead to an improvement in HR-QOL when compared to the unaided condi-
tion. Using HR-QOL measures, outcomes with different pBCIs were in favour of the 
Ponto than the BAHA which was reflected in patient preferences. Comparison of 
pBCI with tBCI and MEI generally showed a similar distribution. Outcomes were 
relatively better with MEI than pBCI on one questionnaire. Outcomes of tBCIs and 
MEIs were also similar on HR-QOL measures, but were slightly in favour of the lat-
ter on a general-health QOL measure (G-QOL). The common HUI G-QOL measure 
was only available for pBCI and MEI users with any type of hearing loss, and results 
were similarly distributed. ConClusions: There are many QOL measures for 
assessing hearing loss, however not many are sensitive at picking up differences 
between hearing implants. The studies identified in the literature, even though 
limited in number and quality, suggest health-related measures to be more sensi-
tive than general health measures.
